

DRUG SAFETY NOTICE

DRUG NAME/STRENGTH/FORM:

Pabrinex Intravenous High Potency, Concentrate for Solution for Infusion

PROBLEM

- There is currently a shortage of Pabrinex Intravenous High Potency, Concentrate for Solution for Infusion.
- This is expected to resolve during week commencing 11th December 2023.
- Limited stock is available in the interim.

ADVICE / ALTERNATIVE

- Limited stock remains available within the Trust.
- Pabrinex is used to prevent Wernicke's encephalopathy / Korsakoff's psychosis in alcohol withdrawal and in those at risk of refeeding syndrome.
- Oral vitamin products are available but not suitable for all patients.

ACTIONS

- Ensure Pabrinex is used in line with Trust guidelines and the BNF.
- Use Pabrinex judiciously to conserve stock for patients with no other treatment options.
 - Review current Pabrinex prescriptions
 - Consider oral thiamine / multivitamins for appropriate patients.

FOR FURTHER INFORMATION CONTACT

PHARMACY DEPARTMENT: CITY x5263; SANDWELL x3783

DATE OF ISSUE: 07/12/2023 REFERENCE NUMBER: 03-1223